Abstract:Considerable efforts have been made to the development of small-molecule inhibitors of antiapoptotic B-cell lymphoma2 (Bcl-2) family proteins (such as Bcl-2, Bcl-x(L), and Mcl-1) as a new class of anticancer therapies. Unlike general inhibitors of the entire family, selective inhibitors of each member protein can hopefully reduce the adverse side effects in chemotherapy treatments of cancers overexpressing different Bcl-2 family proteins. In this study, we designed four series of benzylpiperazine derivatives as plausible Bcl-2 inhibitors based on the outcomes of a computational algorithm. A total of 81 compounds were synthesized, and their binding affinities to Bcl-2, Bcl-x(L), and Mcl-1 measured. Encouragingly, 22 compounds exhibited binding affinities in the micromolar range (K-i<20M) to at least one target protein. Moreover, some compounds were observed to be highly selective binders to Mcl-1 with no detectable binding to Bcl-2 or Bcl-x(L), among which the most potent one has a K-i value of 0.18M for Mcl-1. Binding modes of four selected compounds to Mcl-1 and Bcl-x(L) were derived through molecular docking and molecular dynamics simulations. It seems that the binding affinity and selectivity of these compounds can be reasonably interpreted with these models. Our study demonstrated the possibility for obtaining selective Mcl-1 inhibitors with relatively simple chemical scaffolds. The active compounds identified by us could be used as lead compounds for developing even more potent selective Mcl-1 inhibitors with potential pharmaceutical applications.

Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions.

Structure-Based Optimization of Small-Molecule Inhibitors for the Β-Catenin/b-cell Lymphoma 9 Protein-Protein Interaction.

Discovery Of An Orally Bioavailable Small-Molecule Inhibitor For The Beta-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction

Discovery of 2-(3-(3-carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives As Novel Small-Molecule Inhibitors of the Β-Catenin/b-cell Lymphoma 9 Protein–Protein Interaction

New ZW4864 Derivatives as Small-Molecule Inhibitors for the beta-Catenin/BCL9 Protein-Protein Interaction

Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Design, Synthesis and Biological Evaluation of Quercetin Derivatives As Novel Β-Catenin/b-cell Lymphoma 9 Protein−protein Interaction Inhibitors

Recent advances in -catenin/BCL9 protein-protein interaction inhibitors

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

Rational Design of Small-Molecule Inhibitors for Β-Catenin/t-cell Factor Protein–Protein Interactions by Bioisostere Replacement

Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.

Molecular docking-aided identification of small molecule inhibitors targeting β-catenin-TCF4 interaction

Pharmacological Inhibition of Β-Catenin/bcl9 Interaction Overcomes Resistance to Immune Checkpoint Blockades by Modulating T Reg Cells

Structure‐Based Design of Bicyclic Helical Peptides That Target the Oncogene β‐Catenin

Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy through the Activation of Antigen Presentation of cDC1 Cells

Discovery of small molecule modulators targeting β-catenin interactions using molecular docking and molecular dynamics strategy

Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners

De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.

Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.

Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the Β-Catenin/b-cell Lymphoma 9 Interaction As a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer